|
|
 |
 |
| |
 Printable version |
EGFR/HER1: a target life |
Bulletin du Cancer. Volume 99, Number 2, 181-9, Février 2012, Synthèse
|
 Résumé
Texte intégral
|
Author(s) : Erika Viel, Elsa Curtit, Laura Mansi, Stéphane Vignot |
Summary : EGFR may be considered as an old target, which can be inhibited both by monoclonal antibodies and tyrosine kinase inhibitors. Those molecular targeted strategies are now approved in a wild range of tumors: colorectal cancer, lung cancer, pancreatic cancer and head and neck cancer. This paper proposes to describe the development of anti-EGFR drugs, highlighting several strategies points. Predicting biomarkers have been extensively studied for these agents, sustaining the hallmarks of the development of molecular targeting drugs. |
Keywords : HER1, EGFR, molecular targeted therapy, predictive factors, KRAS, cetuximab, panitumumab, gefitinib, erlotinib |
|
